Back to top
more

Patterson Companies (PDCO)

(Real Time Quote from BATS)

$21.52 USD

21.52
164,975

-0.41 (-1.87%)

Updated Sep 5, 2024 11:24 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value F Growth F Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 32% (170 out of 251)

Industry: Medical - Dental Supplies

Better trading starts here.

Zacks News

Patterson Companies (PDCO) Q2 Earnings Beat, Sales Hurt by FX

Patterson Companies' (PDCO) fiscal second-quarter 2023 results reflect unfavorable currency movements.

Patterson Cos. (PDCO) Q2 Earnings Beat Estimates

Patterson Cos. (PDCO) delivered earnings and revenue surprises of 10.53% and 3.26%, respectively, for the quarter ended October 2022. Do the numbers hold clues to what lies ahead for the stock?

Earnings Preview: Patterson Cos. (PDCO) Q2 Earnings Expected to Decline

Patterson Cos. (PDCO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Patterson Companies' (PDCO) New Buyout to Expand Product Suite

Patterson Companies' (PDCO) latest buyout is expected to significantly expand its Animal Health's product offerings.

Exagen Inc. (XGN) Reports Q3 Loss, Tops Revenue Estimates

Exagen Inc. (XGN) delivered earnings and revenue surprises of 38.16% and 61.24%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Here's Why You Should Retain Patterson Companies (PDCO) Stock

Investors remain optimistic about Patterson Companies (PDCO) on the back of its strong product line.

Patterson Companies (PDCO) Inks Deal to Expand Product Suite

Patterson Companies' (PDCO) latest buyout is expected to significantly expand its value-add platform.

ITeos Therapeutics, Inc. (ITOS) Lags Q3 Earnings and Revenue Estimates

iTeos Therapeutics, Inc. (ITOS) delivered earnings and revenue surprises of -57.14% and 53.65%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Invacare (IVC) Reports Q3 Loss, Misses Revenue Estimates

Invacare (IVC) delivered earnings and revenue surprises of -45.95% and 13.93%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Reasons to Retain AmerisourceBergen (ABC) in Your Portfolio

AmerisourceBergen (ABC) continues to gain traction from the robust U.S. Healthcare Solutions segment. However, stiff competition is a woe.

Here's Why Investors Should Hold Myriad Genetics (MYGN) Now

Myriad Genetics' (MYGN) expansion across the globe, banking on myChoiceCDx test sales, seems impressive.

Here's Why You Should Retain Patterson Companies (PDCO) Stock

Investors remain optimistic about Patterson Companies (PDCO) on the back of its strong product line.

Chemed's (CHE) Roto-Rooter Growth Aids, Macro Challenges Ail

Chemed's (CHE) VITAS segment revenue decline during the second quarter gets somewhat offset by a geographically weighted average Medicare reimbursement rate increase of nearly 1.3%.

Haemonetics (HAE) Business Recovery Continues, Macro Issues Ail

Despite sluggish results of Haemonetics' (HAE) Blood Center business, Whole Blood revenues grow on favorable order timing among distributors in the Asia Pacific and EMEA.

Company News for Sep 2, 2022

Companies in The News Are:CIEN,OLLI,SAIC,PDCO

Here's Why You Should Hold on to Chemed (CHE) Stock Now

Investors are optimistic about Chemed's (CHE) better-than-expected earnings and impressive Roto-Rooter results.

Medtronic (MDT) Obtains U.S. Distribution Rights for BioButton

Medtronic's (MDT) new deal with BioIntelliSense will ensure accessibility to BioButton for continuous vital sign measurements of general care patients in the United States.

Boston Scientific (BSX) Grows Operationally Amid Macro Issues

In the Asia Pacific region, Boston Scientific (BSX) grows operationally with notable performance in Japan, India and the ASEAN countries.

Patterson Companies (PDCO) Q1 Earnings & Sales Miss Estimates

Patterson Companies' (PDCO) fiscal first-quarter 2023 results were adversely impacted by unfavorable currency movements.

Patterson Cos. (PDCO) Lags Q1 Earnings and Revenue Estimates

Patterson Cos. (PDCO) delivered earnings and revenue surprises of -15.79% and 2.50%, respectively, for the quarter ended July 2022. Do the numbers hold clues to what lies ahead for the stock?

Henry Schein (HSIC) Inks Deal to Acquire Midway Dental Supply

Henry Schein's (HSIC) acquisition of Midway Dental Supply complements its efforts to offer products and services that deliver more effective, high-quality patient care.

Bruker (BRKR) Debuts Innovations for Proteomics & Metabolomics

Bruker's (BRKR) novel nanoElute 2 and next-generation MetaboScape 2023 release are likely to offer enhanced workflows for proteomics and metabolomics applications.

Reasons Why You Should Retain ResMed (RMD) Stock For Now

Investors are optimistic about ResMed's (RMD) better-than-expected results and robust device sales.

Haemonetics (HAE) Inks Epic Deal to Expand Hospital Business

According to Haemonetics (HAE), amid the complex situation of blood supply and staffing shortages, the SafeTrace Tx transfusion management system is set to provide more transfusion safety and efficiency.

Here's Why You Should Hold on to Nevro (NVRO) Stock for Now

Investors continue to be optimistic about Nevro (NVRO), owing to its strength in the global SCS market.